TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Distinguishing progression from pseudoprogression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Final diastolic and systolic volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricule viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oral Health-Related Quality Of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and severity of serious adverse events deemed possibly related to CYP-001
Endpoint domain: Adverse events/effects
Primary endpoint: tear film thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal epithelium defect percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Daily Low Back Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Coma Recovery Scale - Revised (CRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Minutes From Visualizing the Target to Reaching the Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of root canal therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-ischaemic venous flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of errors on cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Response Rates to TB Antigens as Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: successful palliation of symptomatic pleural effusions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: changes in body posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OSWESTRY questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF 36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of intracranial hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Risk of ischemic events
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline on the Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical outcomes of ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propofol brain concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complexity of physiological response from ECG data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in attentional bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in startle response -heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complications related to use of pressure wire
Endpoint domain: Adverse events/effects
Primary endpoint: Wrinkle Severity Rating Scale (WSRS) grade variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Volume Loss Scale (FVLS) grade variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects achieving at least a 30% reduction in cyclin D1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peripheral immune markers (cytokines)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain neurotransmitters (glutamate, GABA, myoinositol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skeletal muscle oxygenation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthetic valve dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage change in lesion surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Local Regional Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to incident heart failure event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vocal acoustic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal aerodynamic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Film changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age at the Time of the First NOAC Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHA2DS2-VASc Scores at the Time of the First NOAC Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAS-BLED Score at the Time of the First NOAC Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Ratio of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Achieved SRH Area ≥25mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of average stiffness within the tumour to average stiffness in the stroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to general anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Metformin Tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Acute skin toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Late skin toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subcutaneous tissue toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Western Ontario and McMaster Universities Arthrosis Index (WOMAC) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain intensity and quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to neuromuscular conditions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall Improvement Rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Patients With Virological Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of abnormal fetal heart rate detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: LDT600 plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and Active Ghrelin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Results of physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG recording
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vital signs (Blood Pressure and Pulse Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: identification of pancreatic neoplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Microdialysate torisel concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Adduction Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Influenza Virus Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak Change From Baseline in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics of gefapixant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of biopsy proven acute rejection requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rabies neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone marrow minimal residual disease (MRD) negative complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Colour vision during hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Number of passes with Fitbit wristband
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The 2 minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Self-Efficacy in Multiple Sclerosis Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Naturalness of Expression in Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thyroid nodule's volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: C
Endpoint domain: Adverse events/effects
Primary endpoint: D
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Post-treatment Subjective New or Increased Symptoms (NOIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dental caries progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in switch costs (response time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local control of early stage prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weekly average foot pain severity scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Responder Patients (Structural Remodelling)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Potential Participants Approached Who Were Eligible for the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Eligible Participants Who Agreed to Participate in the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Received Referrals for Homelessness Prevention and/or Substance Use Services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects with Pain Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Co2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: brain structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overactivity of the renin/aldosterone system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Goal Attainment Scale (GAS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in walking distance to onset of leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in walking distance to maximal leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in the Continuity of Attention Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Difference in magnetic activity of smooth muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Strain ratio for all lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical block success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in severity of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in serum IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in HbA1c Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Tau Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Necrotic Core Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tympanic membrane visuality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Periodontal pocket erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Urine Albumin Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Decrease in DAIBD Score of 20 or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean amount of plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stem cell mobilization success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with optimal physiology result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with optimal anatomy result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with optimal physiology and anatomy result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal Report of Confidence as a Speaker
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear of Negative Evaluation-Brief Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician Global Impressions of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of adenovirus-36 positivity in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in MMSE scale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total number of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in formant frequency for vowels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in formant bandwidth for vowels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time to produce individual phonemes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Western Aphasia Battery score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage decrease in B cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Aggression measured by Overt Aggression Scale-Modified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety measured by State-Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Grade II to IV acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Trace elements plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of rosuvastatin vs atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic efficacy on the endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brain MRI imaging data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neurofilament light chain (NfL) in serum and/or plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral spinal fluid (CSF) measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantitative movement assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC^0-inf of coagulation factor VIII activity (FVIII:C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC^0-inf of von Willebrand factor: Ristocetin cofactor activity (VWF:RCo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Half-life of FVIII:C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse events during verticalization
Endpoint domain: Adverse events/effects
Primary endpoint: Total Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: fasting and post glucose load glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GIQli
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-50
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative incidence of CNS-relapse
Endpoint domain: Mortality/survival
Primary endpoint: Estimated probability of event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Ability to ablate fibroid tissue measured by temperature elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to ablate fibroid tissue indicated by Non-Perfused Volume (NPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the system measured by collection of adverse events related to potential damage to tissue outside the treatment zone
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Participant Reported Average Bladder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of methacholine challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with knee surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient state score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation changes in limbic and paralimbic neural circuitry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: antibody concentrations to pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathological lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Remission of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance (percentage of complete datasets)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Capability of and burden for participants of the use of DIY tools
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: intestinal absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Positive Recurrent Adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects Achieving Primary Triple Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes